Monorail neuro-microcatheter for delivery of medical devices to treat stroke, processes and products thereby

Information

  • Patent Grant
  • 8545514
  • Patent Number
    8,545,514
  • Date Filed
    Friday, April 10, 2009
    15 years ago
  • Date Issued
    Tuesday, October 1, 2013
    10 years ago
Abstract
Devices, processes and systems facilitate and enable treatment of acute stroke conditions, providing reperfusion while therapy is made available by preserving structure in the arterial tree. Using a Rapid Exchange approach with at least dual lumens in a microcatheter facilitates embolus/clot removal without damaging sensitive vasculature.
Description
BACKGROUND OF THE DISCLOSURE

This present disclosure relates to minimally invasive surgical devices, methods and systems. In particular, the present disclosure relates to systems designed to mitigate, extenuate or otherwise address acute stroke.


SUMMARY OF THE DISCLOSURE

Briefly stated, novel devices, improved processes and systems facilitate survival from, and preserve best options for, treatment of stroke.


According to embodiments there is disclosed a process for reperfusion during embolus removal comprising; providing a rapid exchange microcatheter system have at least two lumens, emplacing a microcatheter from the system within a blood vessel in the brain, accessing a desired treatment site, maintaining arterial access including greater support to the arterial tree, and addressing a subject embolus/blood clot.


According to embodiments, a process for making a neuro-monorail microcatheter includes at least one of co-extruding and skiving; co-extruding and skiving and lumen fillings; bonding tubes, and providing a predetermined microcatheter set, cutting a distal segment at 5-50 cm, aligning the same adjacent to a distal section of second microcatheter, placing guidewires in each microcatheter to maintain alignment, and applying short segments of PET along the length to secure and maintain alignment and adjacent status of the resulting device.


According to embodiments, a reperfusion device includes a rapid exchange system comprising a first lumen and a second lumen; a microcatheter disposed within the first lumen, comprising a stroke device, wherein the stroke device is expandable; and a guidewire disposed within the second lumen. The stroke device may comprise radiographic marking elements for visualization during placement, wherein the radiographic marking elements may be disposed at a distal end of the stroke device. The stroke device may be tethered, accessible, and retrievable through the microcatheter.





BRIEF DESCRIPTION OF THE FIGURES

The above-mentioned features and objects of the present disclosure will become more apparent with reference to the following description taken in conjunction with the accompanying drawings wherein like reference numerals denote like elements and in which:



FIG. 1 shows a schematic of an exemplary iteration of a device according to the present disclosure in a first position;



FIG. 2 shows a schematic of an exemplary iteration of a device according to the present disclosure in a second position;



FIG. 3 likewise schematically depicts an exemplary iteration of a device according to the present disclosure in a third position.



FIG. 4 illustrates a rapid exchange microcatheter in accordance with an embodiment of the invention.





DETAILED DESCRIPTION OF THE INSTANT TEACHINGS

The present inventors have discovered novel ways to treat strokes. This is done by providing microcatheter devices and therapy schemes whereby access is maintained during capture of emboli/thrombi/clot material without compromise to reperfusion of blood flow. The instant disclosures include microcatheters having at least second lumens for vessel stability during removal of emboli and/or in adjunct therapy modes, these devices are referred to as “Rapid Exchange” or RX systems.


The system of the instant disclosure allows and maintains arterial access to treatment sites, and provides enhanced support to the arterial tree, while working as a rapid exchange system. This enables secure capture of emboli/thrombi/clot material by providing support within the vessel. The RX support provided prevents the proximal vessel from buckling or kinking during tensioning upon embolus removal. This is a key feature, in that the literature is demonstrative of ovalizing, whereby stripping of the embolus from capture devices happens when buckling or kinking happens.


Expressly incorporated by reference as if fully set forth herein are U.S. Letters Patents and Publication Nos. 7,018,372; 6,893,417; and US 2007/0293846; US 2007/0293821; US 2007/0282306; US 2007/0276325; US 2007/0149949; US 2007/0197956.


The pathological course of a blood vessel that is blocked is a gradual progression from reversible ischemia to irreversible infarction (cell death). A stroke is often referred to as a “brain attack” and occurs when a blood vessel in the brain becomes blocked or ruptures. A ischemic stroke occurs when a blood vessel in the brain becomes blocked. Ischemic strokes comprise about 78% of all strokes. A hemorrhagic stroke, which account for the remaining 22% of strokes, occurs when a blood vessel in the brain ruptures. Stroke is the third leading cause of death in the United States, behind heart disease and cancer and is the leading cause of severe, longterm disability. Each year roughly 700,000 Americans experience a new or recurrent stroke. Stroke is the number one cause of inpatient Medicare reimbursement for long-term adult care. Total stroke costs now exceeds $45 billion per year in US healthcare dollars.


Currently there are only two FDA-approved mechanical treatment options for acute ischemic stroke. One option is a thrombo-embolectomy device. In August of 2004, Concentric Medical received FDA approval for its MERCI™ clot removal device. The Merci device is designed to capture an embolus or clot and remove it from the blocked vessel thereby restoring blood flow. The device is designed to be used in conjunction with a microcatheter. The microcatheter must cross the embolus before the Merci device can be deployed. The Merci device design is a cork-screwed guidewire. This device is only able to capture and remove matter that is firm or held together by itself. In most cases Merci breaks up the embolus rather than removes it and is used in combination with drug therapy to restore blood flow. A typical procedure using Merci will take 2-3 hours to restore blood flow if at all and may take multiple passes through the vessel to either capture, macerate or open the vessel. In some cases, the Merci device may capture an embolus but then lose grasp of it and deposit it incidentally in another area arc of the neuro vasculature creating a new stroke in a new territory. In some cases complications such as vessel dissection, perforation and hemorrhage arise as a result of manipulation in the vessel. Some issues in using Merci are that the Merci device itself is a guidewire. Therefore, once it is removed access is lost. Also, as the device is engaging an embolus and being withdrawn proximally, the vessels tend to be pulled with the device and buckle. This action appears to be a great source for the embolus fragmenting and vessel damage. A second option is an aspiration device manufactured by Penumbra, Inc. The embolus is removed by aspirating or sucking from the proximal side. A microwire is passed through the catheter into the embolus to aide in aspirating.


Several methods of treating stroke have been attempted, with varying degrees of success. However, according to the instant teachings, blood can be reperfused or emboli/thrombi/clot material can be removed from the neurovasculature consistently and safely with arterial support and access maintained during the procedure.


Other techniques used in addressing this issue comprise coextruded microcatheters having multi-lumen structures, as would be known to Artisans based on this disclosure and the claims appended hereto.


According embodiments of the present disclosure, an OTW system including a microcatheter having a delivery system tube is combined with a rapid exchange system as discussed above. The OTW system may be configured to fit within a lumen of the RX system. A microcatheter may be configured to fit within another lumen of the RX system. Examples of such a guidewire include Transend® or Synchro® brands. Examples of such a microcatheter include Cordis® MASSTRANSIT® or Renegade™ HI-FLO brands.


In some embodiments, the rapid exchange system comprises an RX microcatheter, a guidewire, a delivery device (e.g., wire or tube), and/or a therapeutic stroke device. In one embodiment, the RX microcatheter is a multi-lumen (e.g., dual-lumen) microcatheter. In one embodiment, the RX microcatheter has a proximal outer diameter of 3.0 F (0.039″) and a distal outer diameter of 3.5 F (0.045″). In one embodiment, a first lumen configured to receive a guidewire has a distal inner diameter of 0.017″ and the second lumen configured to receive the therapeutic stroke device has a distal inner diameter of 0.023″. In one embodiment, the guidewire is a 0.014″×190 cm wire.


The rapid exchange delivery catheter functions with, for example, CORDIS® brands of microcatheters available from them, and may be assembled as detailed below, or as known to those skilled in the art.


Referring now to FIG. 1, according embodiments of the present disclosure, guidewire 99 accesses and crosses a target lesion, providing a pathway for RX microcatheter 101 having at least two lumens. Stroke device 103 is shown in a state of transition from a first (collapsed) position to a second (expanded) position emerging from a lumen of RX microcatheter 101. According to embodiments, guidewire 99 may be at least partially disposed within one of the two lumens of RX microcatheter 101.


Referring now to FIG. 2, according embodiments of the present disclosure, stroke device 103 includes radiographic marking elements 105 for visualization during placement. Likewise, those skilled in the art readily accomplished using the system of the present invention.


Referring now also to FIG. 3, according embodiments of the present disclosure, stroke device 103 is shown in a fully expanded position, whereby it functions consistently and safely such that arterial support is maintained in virtue of guidewire 99 keeping the arterial tree from mechanical stress, while embolus removal, clot capture and other procedures are done. Thus, reperfusion is established and therapy administered without risks to patients present with other devices. According to embodiments, as shown in FIG. 3, stroke device 103 may be tethered such that, while emplaced at a treatment site within a blood vessel, it remains accessible via a microcatheter and readily retrievable therein while maintaining reperfusion of the blood vessel. In one embodiment, the stroke device is tethered to the delivery device via tethered lines. According to embodiments, stroke device 103 may be emplaced on a long-term or permanent basis, or as needed based on the amount and type of recanalization prescribed. According to embodiments, stroke device 103 is self-expandable, such that is may expand substantially radially when removed from within the catheter. According to embodiments, additional therapies may be provided while stroke device 103 is fully expanded, for example, through another lumen of RX microcatheter 101.


According to embodiments of the present disclosure, a process for making a neuro-monorail microcatheter is disclosed. The process may include cutting a first microcatheter at a distal end. A segment may be cut at about 5 cm to 50 cm from a distal end of the microcatheter. The segment of the first catheter may be aligned adjacent to a distal section of a second microcatheter. Guidewires may be placed in each of first and second microcatheters to maintain their respective alignments and keep their lumens open. A resin, such as Polyethylene terephthalate (PET), may be applied in short segments along the lengths of the first and second microcatheters to secure and maintain alignment and adjacent status of the finished device.


According to embodiments of the present disclosure, a first and second catheter, as described above, may be co-extruded and skived, in lieu of the cutting discussed above, and joined as discussed above. In one embodiment, the segment of the neuro-monorail microcatheter configured to receive a guidewire can have a length of about 35 cm to about 40 cm. In one embodiment, the segment of the neuro-monorail microcatheter configured to receive a guidewire can extend 35 cm from the distal end of the neuro-monorail microcatheter.



FIG. 4 illustrates a rapid exchange microcatheter 401 in accordance with an embodiment of the invention. The rapid exchange microcatheter 401 includes a first lumen and a second lumen. The second lumen is within a rapid exchange segment 402 of the rapid exchange microcatheter 401 having a length L. As shown, the guidewire 99 can be inserted within the second lumen of the rapid exchange segment 402. The length L of the rapid exchange segment 402 (and the second lumen within) can range from about 5 cm to 50 cm. In some embodiments, the length L can range from about 35 cm to about 40 cm to provide support within the cerebral vasculature (for example, to facilitate movement of the guidewire within tortuous regions of the cerebral vasculature or to prevent buckling or kinking of vessels of the cerebral vasculature).


While the method and agent have been described in terms of what are presently considered to be the most practical and preferred embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.


It should also be understood that a variety of changes may be made without departing from the essence of the invention. Such changes are also implicitly included in the description. They still fall within the scope of this invention. It should be understood that this disclosure is intended to yield a patent covering numerous aspects of the invention both independently and as an overall system and in both method and apparatus modes.


Further, each of the various elements of the invention and claims may also be achieved in a variety of manners. This disclosure should be understood to encompass each such variation, be it a variation of an embodiment of any apparatus embodiment, a method or process embodiment, or even merely a variation of any element of these.


Particularly, it should be understood that as the disclosure relates to elements of the invention, the words for each element may be expressed by equivalent apparatus terms or method terms—even if only the function or result is the same.


Such equivalent, broader, or even more generic terms should be considered to be encompassed in the description of each element or action. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this invention is entitled.


It should be understood that all actions may be expressed as a means for taking that action or as an element which causes that action.


Similarly, each physical element disclosed should be understood to encompass a disclosure of the action which that physical element facilitates.


Any patents, publications, or other references mentioned in this application for patent are hereby incorporated by reference. In addition, as to each term used it should be understood that unless its utilization in this application is inconsistent with such interpretation, common dictionary definitions should be understood as incorporated for each term and all definitions, alternative terms, and synonyms such as contained in at least one of a standard technical dictionary recognized by artisans and the Random House Webster's Unabridged Dictionary, latest edition are hereby incorporated by reference.


Finally, all referenced listed in the Information Disclosure Statement or other information statement filed with the application are hereby appended and hereby incorporated by reference; however, as to each of the above, to the extent that such information or statements incorporated by reference might be considered inconsistent with the patenting of this/these invention(s), such statements are expressly not to be considered as made by the applicant(s).


In this regard it should be understood that for practical reasons and so as to avoid adding potentially hundreds of claims, the applicant has presented claims with initial dependencies only.


Support should be understood to exist to the degree required under new matter laws—including but not limited to United States Patent Law 35 USC 132 or other such laws—to permit the addition of any of the various dependencies or other elements presented under one independent claim or concept as dependencies or elements under any other independent claim or concept.


To the extent that insubstantial substitutes are made, to the extent that the applicant did not in fact draft any claim so as to literally encompass any particular embodiment, and to the extent otherwise applicable, the applicant should not be understood to have in any way intended to or actually relinquished such coverage as the applicant simply may not have been able to anticipate all eventualities; one skilled in the art, should not be reasonably expected to have drafted a claim that would have literally encompassed such alternative embodiments.


Further, the use of the transitional phrase “comprising” is used to maintain the “open-end” claims herein, according to traditional claim interpretation. Thus, unless the context requires otherwise, it should be understood that the term “comprise” or variations such as “comprises” or “comprising”, are intended to imply the inclusion of a stated element or step or group of elements or steps but not the exclusion of any other element or step or group of elements or steps.


Such terms should be interpreted in their most expansive forms so as to afford the applicant the broadest coverage legally permissible.

Claims
  • 1. A dual lumen reperfusion system for insertion into cerebral vasculature for the treatment of ischemic stroke, comprising, in combination: a rapid exchange microcatheter comprising a proximal end, a distal end, a first lumen, and a second lumen separate from the first lumen, both the first lumen and the second lumen terminating distally at the distal end of the rapid exchange microcatheter, the first lumen terminating proximally at the proximal end of the rapid exchange microcatheter;wherein the rapid exchange microcatheter is dimensioned for delivery in tortuous cerebral vasculature;a delivery device disposed within the first lumen;wherein the delivery device is coupled to a stroke device, wherein the stroke device is self-expandable;wherein the stroke device is configured to facilitate reperfusion and removal of one or more stroke-inducing emboli within a blood vessel in the brain;a guidewire disposed within the second lumen; andwherein the second lumen is housed by a segment of the rapid exchange microcatheter that has a length that is less than an entire length of the rapid exchange microcatheter and in the range of about 5 cm to about 50 cm to facilitate movement of the guidewire through the tortuous cerebral vasculature.
  • 2. The reperfusion system of claim 1, wherein the stroke device comprises radiographic marking elements for visualization during placement.
  • 3. The reperfusion system of claim 2, wherein the radiographic marking elements are disposed at a distal end of the stroke device.
  • 4. The reperfusion system of claim 1, wherein the stroke device is tethered to the delivery device and accessible through the microcatheter.
  • 5. The reperfusion system of claim 1, wherein the stroke device is retrievable through the microcatheter.
  • 6. The reperfusion system of claim 1, wherein the second lumen is housed by a segment of the microcatheter that has a length of about 35 cm to about 40 cm.
  • 7. A dual lumen reperfusion system for insertion into cerebral vasculature for the treatment of ischemic stroke, comprising: a rapid exchange microcatheter comprising a proximal end, a distal end, a first lumen, and a second lumen separate from the first lumen, the first lumen extending from the distal end to the proximal end, and the second lumen extending from the distal end to a location between the proximal end and the distal end;a delivery device disposed within the first lumen, comprising a stroke device, wherein the stroke device is expandable; anda guidewire disposed within the second lumen;wherein the second lumen is housed by a segment of the rapid exchange microcatheter that has a length in the range of about 35 cm to about 40 cm to provide support within the cerebral vasculature.
  • 8. The reperfusion system of claim 7, wherein the stroke device is coupled to the delivery device via tethered lines.
  • 9. A reperfusion system for insertion into cerebral vasculature for the treatment of ischemic stroke, comprising: a rapid exchange microcatheter comprising a first catheter and a second catheter, the first catheter having a first length and defining a first lumen extending the first length, the second catheter having a second length and defining a second lumen extending the second length, the first length being greater than the second length, the second catheter extending adjacent to a distal section of the first catheter with a distal end of the second catheter aligned with a distal end of the first catheter;a delivery device disposed within the first lumen, comprising a stroke device, wherein the stroke device is expandable; anda guidewire disposed within the second lumen.
  • 10. The reperfusion system of claim 9, wherein the first catheter and the second catheter are co-extruded.
RELATED APPLICATION

This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/044,392, filed Apr. 11, 2008; U.S. Provisional Application Ser. No. 61/057,613, filed on May 30, 2008; U.S. Provisional Application Ser. No. 61/166,725, filed Apr. 4, 2009; the contents of which are incorporated by reference herein in their entirety.

US Referenced Citations (549)
Number Name Date Kind
2709999 Nagel Jun 1955 A
3174851 Buehler et al. Mar 1965 A
3351463 Rozner et al. Nov 1967 A
3506171 Rupert Apr 1970 A
3753700 Harrison et al. Aug 1973 A
4650466 Luther Mar 1987 A
4993481 Kamimoto et al. Feb 1991 A
4998539 Delsanti Mar 1991 A
5035686 Crittenden et al. Jul 1991 A
5057114 Wittich et al. Oct 1991 A
5222964 Cooper Jun 1993 A
5222971 Willard et al. Jun 1993 A
5275622 Lazarus et al. Jan 1994 A
5327885 Griffith Jul 1994 A
5344395 Whalen Sep 1994 A
5370653 Cragg Dec 1994 A
5425739 Jessen Jun 1995 A
5449372 Schmaltz Sep 1995 A
5456667 Ham et al. Oct 1995 A
5527282 Segal Jun 1996 A
5643309 Myler et al. Jul 1997 A
5649906 Gory et al. Jul 1997 A
5653743 Martin Aug 1997 A
5681336 Clement et al. Oct 1997 A
5683449 Marcade Nov 1997 A
5695469 Segal Dec 1997 A
5718724 Goicoechea et al. Feb 1998 A
5792157 Mische et al. Aug 1998 A
5795322 Boudewijn Aug 1998 A
5800457 Gelbfish Sep 1998 A
5800519 Sandock Sep 1998 A
5827324 Cassell et al. Oct 1998 A
5853419 Imran Dec 1998 A
5916235 Guglielmi Jun 1999 A
5922019 Hankh et al. Jul 1999 A
5928260 Chin Jul 1999 A
5938671 Katoh Aug 1999 A
5938697 Killion et al. Aug 1999 A
5941895 Myler et al. Aug 1999 A
5947995 Samuels Sep 1999 A
5951599 McCrory Sep 1999 A
5961547 Razavi Oct 1999 A
5968013 Smith et al. Oct 1999 A
5972016 Morales Oct 1999 A
5972019 Engelson Oct 1999 A
5972219 Habets Oct 1999 A
5976120 Chow et al. Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
6001118 Daniel et al. Dec 1999 A
6010449 Selmon et al. Jan 2000 A
6010498 Guglielmi Jan 2000 A
6010521 Lee et al. Jan 2000 A
6015424 Rosenbluth et al. Jan 2000 A
6039721 Johnson Mar 2000 A
6051020 Goicoechea et al. Apr 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson May 2000 A
6093199 Brown et al. Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6117167 Goicoechea et al. Sep 2000 A
6123115 Greenhalgh Sep 2000 A
6136006 Johnson et al. Oct 2000 A
6146396 Konya et al. Nov 2000 A
6159238 Killion et al. Dec 2000 A
6159239 Greenhalgh Dec 2000 A
6164339 Greenhalgh Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168604 Cano Jan 2001 B1
6190358 Fitzmaurice Feb 2001 B1
6192944 Greenhalgh Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6210364 Anderson Apr 2001 B1
6217609 Haverkost Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6231598 Berry et al. May 2001 B1
6238430 Klumb et al. May 2001 B1
6280413 Clark et al. Aug 2001 B1
6283940 Mullholland Sep 2001 B1
6283992 Hankh et al. Sep 2001 B1
6290720 Khosravi et al. Sep 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6305436 Andersen et al. Oct 2001 B1
6306141 Jervis Oct 2001 B1
6322585 Khosravi et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6325820 Khosravi et al. Dec 2001 B1
6325822 Chouinard et al. Dec 2001 B1
6344041 Kupiecki et al. Feb 2002 B1
6383205 Samson et al. May 2002 B1
6390993 Cornish et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6454780 Wallace Sep 2002 B1
6458139 Palmer et al. Oct 2002 B1
6468301 Amplatz et al. Oct 2002 B1
6475236 Roubin et al. Nov 2002 B1
6475237 Drasler et al. Nov 2002 B2
6485500 Kokish Nov 2002 B1
6485509 Killion et al. Nov 2002 B2
6537294 Boyle et al. Mar 2003 B1
6551341 Boylan et al. Apr 2003 B2
6551342 Shen et al. Apr 2003 B1
6553810 Webb et al. Apr 2003 B2
6554856 Doorly et al. Apr 2003 B1
6558405 McInnes May 2003 B1
6562066 Martin May 2003 B1
6569179 Teoh et al. May 2003 B2
6569193 Cox et al. May 2003 B1
6575997 Palmer et al. Jun 2003 B1
6589265 Palmer et al. Jul 2003 B1
6592607 Palmer et al. Jul 2003 B1
6592615 Marcade et al. Jul 2003 B1
6605057 Fitzmaurice Aug 2003 B2
6610077 Hancock et al. Aug 2003 B1
6616617 Ferrera et al. Sep 2003 B1
6629953 Boyd Oct 2003 B1
6632241 Hancock et al. Oct 2003 B1
6635081 Khosravi et al. Oct 2003 B2
6638294 Palmer Oct 2003 B1
6641590 Palmer et al. Nov 2003 B1
6652505 Tsugita Nov 2003 B1
6652576 Stalker Nov 2003 B1
6660021 Palmer et al. Dec 2003 B1
6663607 Slaikeu et al. Dec 2003 B2
6666829 Cornish et al. Dec 2003 B2
6669723 Killion et al. Dec 2003 B2
6673025 Richardson et al. Jan 2004 B1
6685722 Rosenbluth Feb 2004 B1
6685738 Chouinard et al. Feb 2004 B2
6695813 Boyle et al. Feb 2004 B1
6702843 Brown et al. Mar 2004 B1
6709440 Callol et al. Mar 2004 B2
6716178 Kilpatrick et al. Apr 2004 B1
6723112 Ho et al. Apr 2004 B2
6730104 Sepetka et al. May 2004 B1
6733519 Lashinski May 2004 B2
6746468 Sepetka et al. Jun 2004 B1
6764506 Roubin et al. Jul 2004 B2
6773454 Wholey et al. Aug 2004 B2
6790237 Stinson Sep 2004 B2
6795979 Fournier Sep 2004 B2
6802851 Jones et al. Oct 2004 B2
6818015 Hankh et al. Nov 2004 B2
6821291 Bolea et al. Nov 2004 B2
6824558 Parodi Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6840958 Nunez et al. Jan 2005 B2
6881220 Edwin et al. Apr 2005 B2
6893413 Martin May 2005 B2
6913612 Palmer et al. Jul 2005 B2
6949620 Aida et al. Sep 2005 B2
6953472 Palmer et al. Oct 2005 B2
6955685 Escamilla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6991641 Diaz et al. Jan 2006 B2
6994723 McMahon Feb 2006 B1
7001422 Escamilla et al. Feb 2006 B2
7004954 Voss Feb 2006 B1
7004955 Shen et al. Feb 2006 B2
7004956 Palmer et al. Feb 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7029688 Hubbell et al. Apr 2006 B2
7037329 Martin May 2006 B2
7041116 Goto et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7056328 Arnott Jun 2006 B2
7056336 Armstrong et al. Jun 2006 B2
7060091 Killion et al. Jun 2006 B2
7089218 Visel Aug 2006 B1
7112217 Kugler et al. Sep 2006 B1
7118600 Dua et al. Oct 2006 B2
7125419 Sequin et al. Oct 2006 B2
7128736 Abrams et al. Oct 2006 B1
7144421 Carpenter et al. Dec 2006 B2
7147655 Chermoni Dec 2006 B2
7147660 Chobotov et al. Dec 2006 B2
7156869 Pacetti Jan 2007 B1
7160317 McHale Jan 2007 B2
7169165 Belef et al. Jan 2007 B2
7172575 El-Nounou Feb 2007 B2
7172617 Colgan et al. Feb 2007 B2
7175607 Lim Feb 2007 B2
7179273 Palmer et al. Feb 2007 B1
7179284 Khosravi et al. Feb 2007 B2
7201769 Jones et al. Apr 2007 B2
7201770 Johnson Apr 2007 B2
7223284 Khosravi et al. May 2007 B2
7238197 Sequin et al. Jul 2007 B2
7240516 Pryor Jul 2007 B2
7241301 Thramann et al. Jul 2007 B2
7279003 Berra et al. Oct 2007 B2
7279292 Imam et al. Oct 2007 B2
7285126 Sepetka et al. Oct 2007 B2
7294147 Hartley Nov 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306619 Palmer Dec 2007 B1
7309345 Wallace Dec 2007 B2
7309351 Escamilla Dec 2007 B2
7323000 Monstdt et al. Jan 2008 B2
7323005 Wallace et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7326240 Caro et al. Feb 2008 B1
7344550 Carrison et al. Mar 2008 B2
7344556 Sequin et al. Mar 2008 B2
7351255 Andreas Apr 2008 B2
7354455 Stinson Apr 2008 B2
7402169 Killion et al. Jul 2008 B2
7407509 Greenberg et al. Aug 2008 B2
7435254 Chouinard et al. Oct 2008 B2
7438720 Shaked Oct 2008 B2
7455646 Richardson et al. Nov 2008 B2
7473272 Pryor Jan 2009 B2
7494474 Richardson et al. Feb 2009 B2
7549974 Nayak Jun 2009 B2
7691122 Dieck et al. Apr 2010 B2
7727242 Sepetka et al. Jun 2010 B2
7727243 Sepetka et al. Jun 2010 B2
7749243 Phung Jul 2010 B2
7780694 Palmer et al. Aug 2010 B2
7833240 Okushi et al. Nov 2010 B2
7972342 Gandhi et al. Jul 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8062307 Sepetka et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8100918 Gandhi et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8105333 Sepetka et al. Jan 2012 B2
8197493 Ferrera et al. Jun 2012 B2
20010000797 Mazzocchi May 2001 A1
20010004705 Killion et al. Jun 2001 A1
20010010013 Cox et al. Jul 2001 A1
20010031981 Evans et al. Oct 2001 A1
20010034531 Ho et al. Oct 2001 A1
20010044633 Klint Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20010047202 Slaikeu et al. Nov 2001 A1
20010051823 Khosravi et al. Dec 2001 A1
20020004681 Teoh et al. Jan 2002 A1
20020007210 Chouinard et al. Jan 2002 A1
20020016564 Courtney et al. Feb 2002 A1
20020016624 Patterson Feb 2002 A1
20020032479 Hankh et al. Mar 2002 A1
20020038142 Khosravi et al. Mar 2002 A1
20020038146 Harry Mar 2002 A1
20020052643 Wholey et al. May 2002 A1
20020068968 Hupp Jun 2002 A1
20020072790 McGuckin, Jr. et al. Jun 2002 A1
20020087209 Edwin et al. Jul 2002 A1
20020091355 Hayden Jul 2002 A1
20020095141 Belef Jul 2002 A1
20020143387 Soetikno et al. Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020169458 Connors Nov 2002 A1
20020183831 Rolando et al. Dec 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20030004536 Boylan et al. Jan 2003 A1
20030023230 Lewis et al. Jan 2003 A1
20030023299 Amplatz et al. Jan 2003 A1
20030032941 Boyle et al. Feb 2003 A1
20030032977 Brady Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030055440 Jones et al. Mar 2003 A1
20030055451 Jones et al. Mar 2003 A1
20030074056 Killion et al. Apr 2003 A1
20030078605 Bashiri et al. Apr 2003 A1
20030097114 Ouriel et al. May 2003 A1
20030105484 Boyle Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125798 Martin Jul 2003 A1
20030130719 Martin Jul 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139803 Sequin et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030176914 Rabkin et al. Sep 2003 A1
20030199921 Palmer et al. Oct 2003 A1
20030204202 Palmer et al. Oct 2003 A1
20040002752 Griffin et al. Jan 2004 A1
20040006306 Evans et al. Jan 2004 A1
20040006381 Sequin et al. Jan 2004 A1
20040019322 Hoffmann Jan 2004 A1
20040030378 Khosravi et al. Feb 2004 A1
20040034386 Fulton et al. Feb 2004 A1
20040049258 Khosravi et al. Mar 2004 A1
20040054367 Jimenez, Jr. et al. Mar 2004 A1
20040059259 Cornish et al. Mar 2004 A1
20040059407 Escamilla et al. Mar 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073300 Chouinard et al. Apr 2004 A1
20040078071 Escamilla et al. Apr 2004 A1
20040079429 Miller et al. Apr 2004 A1
20040088002 Boyle et al. May 2004 A1
20040102838 Killion et al. May 2004 A1
20040106979 Goicoechea et al. Jun 2004 A1
20040114912 Okamoto et al. Jun 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040147939 Rabkin et al. Jul 2004 A1
20040158307 Jones et al. Aug 2004 A1
20040158312 Chouinard et al. Aug 2004 A1
20040186562 Cox Sep 2004 A1
20040193246 Ferrera Sep 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040215312 Andreas Oct 2004 A1
20040215319 Berra et al. Oct 2004 A1
20040249439 Richter et al. Dec 2004 A1
20040254628 Nazzaro et al. Dec 2004 A1
20040260385 Jones et al. Dec 2004 A1
20050033334 Santra et al. Feb 2005 A1
20050033349 Jones et al. Feb 2005 A1
20050033409 Burke et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050038496 Jones et al. Feb 2005 A1
20050049676 Nazzaro et al. Mar 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050075715 Borges et al. Apr 2005 A1
20050080480 Bolea et al. Apr 2005 A1
20050090857 Kusleika et al. Apr 2005 A1
20050096726 Sequin et al. May 2005 A1
20050102018 Carpenter et al. May 2005 A1
20050107823 Leone et al. May 2005 A1
20050119684 Guterman Jun 2005 A1
20050125023 Bates Jun 2005 A1
20050126979 Lowe Jun 2005 A1
20050131515 Cully et al. Jun 2005 A1
20050131516 Greenhalgh Jun 2005 A1
20050159774 Belef Jul 2005 A1
20050177228 Solem et al. Aug 2005 A1
20050187612 Edwin Aug 2005 A1
20050192661 Griffen et al. Sep 2005 A1
20050209673 Shaked Sep 2005 A1
20050209675 Ton et al. Sep 2005 A1
20050209678 Henkes et al. Sep 2005 A1
20050216050 Sepetka et al. Sep 2005 A1
20050222583 Cano Oct 2005 A1
20050222607 Palmer et al. Oct 2005 A1
20050267570 Shadduck Dec 2005 A1
20050277978 Greenhalgh Dec 2005 A1
20060020285 Niermann Jan 2006 A1
20060020321 Parker Jan 2006 A1
20060025845 Escamilla et al. Feb 2006 A1
20060025850 Feller et al. Feb 2006 A1
20060030865 Balg Feb 2006 A1
20060036281 Patterson Feb 2006 A1
20060052816 Bates et al. Mar 2006 A1
20060058833 VanCamp Mar 2006 A1
20060058836 Bose et al. Mar 2006 A1
20060058838 Bose et al. Mar 2006 A1
20060074480 Bales et al. Apr 2006 A1
20060089703 Escamilla et al. Apr 2006 A1
20060100663 Palmer et al. May 2006 A1
20060106421 Teoh May 2006 A1
20060106448 Shaked May 2006 A1
20060122685 Bonsignore et al. Jun 2006 A1
20060135947 Soltesz et al. Jun 2006 A1
20060142841 Khosravi et al. Jun 2006 A1
20060142849 Killion et al. Jun 2006 A1
20060195172 Luo et al. Aug 2006 A1
20060200048 Furst et al. Sep 2006 A1
20060200221 Malewicz Sep 2006 A1
20060224180 Anderson et al. Oct 2006 A1
20060229645 Bonnette et al. Oct 2006 A1
20060259119 Rucker Nov 2006 A1
20060265054 Greenhalgh et al. Nov 2006 A1
20060271090 Shaked et al. Nov 2006 A1
20060276883 Greenberg et al. Dec 2006 A1
20060287701 Pal Dec 2006 A1
20060287704 Hartley et al. Dec 2006 A1
20070032852 Machek et al. Feb 2007 A1
20070043424 Pryor Feb 2007 A1
20070043425 Hartley et al. Feb 2007 A1
20070055299 Ishimaru et al. Mar 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070055360 Hanson et al. Mar 2007 A1
20070055365 Greenberg et al. Mar 2007 A1
20070067011 Krolik et al. Mar 2007 A1
20070073376 Krolik et al. Mar 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070100425 Sequin et al. May 2007 A1
20070118205 Davidson et al. May 2007 A1
20070123972 Greenberg et al. May 2007 A1
20070135888 Khosravi et al. Jun 2007 A1
20070141036 Gorrochategui Barrueta et al. Jun 2007 A1
20070142896 Anderson et al. Jun 2007 A1
20070156170 Hancock et al. Jul 2007 A1
20070156228 Majercak et al. Jul 2007 A1
20070162109 Davila et al. Jul 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070191924 Rudakov Aug 2007 A1
20070198028 Miloslavski Aug 2007 A1
20070198030 Martin et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070203452 Mehta Aug 2007 A1
20070203559 Freudenthal et al. Aug 2007 A1
20070208367 Fiorella Sep 2007 A1
20070208371 French et al. Sep 2007 A1
20070219621 Hartley et al. Sep 2007 A1
20070225794 Thramann et al. Sep 2007 A1
20070233236 Pryor Oct 2007 A1
20070250040 Provost et al. Oct 2007 A1
20070266542 Melsheimer Nov 2007 A1
20070270932 Headley et al. Nov 2007 A1
20070288034 MacCollum et al. Dec 2007 A1
20070288037 Cheng et al. Dec 2007 A1
20070288080 Maccollum et al. Dec 2007 A1
20070288083 Hines Dec 2007 A1
20070293846 von Oepen et al. Dec 2007 A1
20070299503 Berra et al. Dec 2007 A1
20080001333 Kleine et al. Jan 2008 A1
20080015558 Harlan Jan 2008 A1
20080015682 Majercak et al. Jan 2008 A1
20080033528 Satasiya et al. Feb 2008 A1
20080039926 Majercak et al. Feb 2008 A1
20080039930 Jones et al. Feb 2008 A1
20080045995 Guterman et al. Feb 2008 A1
20080046064 Sequin et al. Feb 2008 A1
20080046072 Laborde et al. Feb 2008 A1
20080051803 Monjtadt Feb 2008 A1
20080058724 Wallace et al. Mar 2008 A1
20080071178 Greenland et al. Mar 2008 A1
20080077175 Palmer Mar 2008 A1
20080082159 Tseng et al. Apr 2008 A1
20080086196 Truckai et al. Apr 2008 A1
20080097495 Feller et al. Apr 2008 A1
20080103477 Jones May 2008 A1
20080103585 Monstadt May 2008 A1
20080109063 Hancock et al. May 2008 A1
20080109067 Caro et al. May 2008 A1
20080114445 Melsheimer et al. May 2008 A1
20080125855 Henkes et al. May 2008 A1
20080140107 Bei et al. Jun 2008 A1
20080140181 Reynolds et al. Jun 2008 A1
20080147100 Wallace et al. Jun 2008 A1
20080161903 Sequin et al. Jul 2008 A1
20080161936 Feller et al. Jul 2008 A1
20080167708 Molland et al. Jul 2008 A1
20080195140 Myla et al. Aug 2008 A1
20080200946 Braun et al. Aug 2008 A1
20080208319 Rabkin et al. Aug 2008 A1
20080221554 O'Connor et al. Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080221664 Bales et al. Sep 2008 A1
20080221671 Chouinard et al. Sep 2008 A1
20080228216 Strauss et al. Sep 2008 A1
20080234795 Snow et al. Sep 2008 A1
20080243229 Wallace et al. Oct 2008 A1
20080243232 Hegg et al. Oct 2008 A1
20080247943 Lanza et al. Oct 2008 A1
20080249598 Sherry Oct 2008 A1
20080255678 Cully et al. Oct 2008 A1
20080262506 Griffin et al. Oct 2008 A1
20080262528 Martin Oct 2008 A1
20080262532 Martin Oct 2008 A1
20080262592 Jordan et al. Oct 2008 A1
20080262952 Channell Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080269868 Bei et al. Oct 2008 A1
20080275497 Palmer et al. Nov 2008 A1
20080275498 Palmer et al. Nov 2008 A1
20080275536 Zarins et al. Nov 2008 A1
20080281302 Murphy et al. Nov 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080281393 Armstrong et al. Nov 2008 A1
20080281397 Killion et al. Nov 2008 A1
20080281403 Kavteladze Nov 2008 A1
20080306503 Que et al. Dec 2008 A1
20080306504 Win et al. Dec 2008 A1
20080312732 Hartley et al. Dec 2008 A1
20080319525 Tieu et al. Dec 2008 A1
20080319533 Lehe Dec 2008 A1
20090018633 Lindquist et al. Jan 2009 A1
20090018634 State Jan 2009 A1
20090018640 State Jan 2009 A1
20090024157 Anukhin Jan 2009 A1
20090025820 Adams Jan 2009 A1
20090030502 Sun et al. Jan 2009 A1
20090036968 Hepworth et al. Feb 2009 A1
20090036977 Rassat et al. Feb 2009 A1
20090062726 Ford et al. Mar 2009 A1
20090062773 Cornish et al. Mar 2009 A1
20090062834 Moftakhar et al. Mar 2009 A1
20090068097 Sevrain Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090069836 Labdag et al. Mar 2009 A1
20090076450 Caizza et al. Mar 2009 A1
20090082800 Janardhan Mar 2009 A1
20090093822 Ducharme Apr 2009 A1
20090105644 Leonard et al. Apr 2009 A1
20090105722 Fulkerson Apr 2009 A1
20090105737 Fulkerson Apr 2009 A1
20090105747 Chanduszko et al. Apr 2009 A1
20090125053 Ferrera et al. May 2009 A1
20090192455 Ferrera et al. Jul 2009 A1
20090292297 Ferrera Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20100022951 Ferrera et al. Jan 2010 A1
20100114017 Lenker et al. May 2010 A1
20100114135 Wilson et al. May 2010 A1
20100137892 Krolik et al. Jun 2010 A1
20100152766 Dieck et al. Jun 2010 A1
20100174309 Fulkerson et al. Jul 2010 A1
20100217187 Fulkerson et al. Aug 2010 A1
20100256600 Ferrera Oct 2010 A1
20100318097 Ferrera et al. Dec 2010 A1
20110009875 Grandfield et al. Jan 2011 A1
20110009941 Grandfield et al. Jan 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110152920 Eckhouse et al. Jun 2011 A1
20110160742 Ferrera et al. Jun 2011 A1
20110160757 Ferrera et al. Jun 2011 A1
20110160760 Ferrera et al. Jun 2011 A1
20110160761 Ferrera et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110166586 Sepetka et al. Jul 2011 A1
20110172699 Miller et al. Jul 2011 A1
20110184456 Grandfield et al. Jul 2011 A1
20110190797 Fulkerson et al. Aug 2011 A1
20110202088 Eckhouse et al. Aug 2011 A1
20110238106 Ferrera et al. Sep 2011 A1
20110270178 Fiorella et al. Nov 2011 A1
20110288572 Martin Nov 2011 A1
20110301686 Bowman et al. Dec 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120016396 Dehnad Jan 2012 A1
20120016406 Ferrera et al. Jan 2012 A1
20120022576 Ferrera et al. Jan 2012 A1
20120022581 Wilson et al. Jan 2012 A1
20120035648 Wilson et al. Feb 2012 A1
20120041411 Horton et al. Feb 2012 A1
20120041449 Eckhouse et al. Feb 2012 A1
20120041459 Fiorella et al. Feb 2012 A1
20120041460 Ferrera et al. Feb 2012 A1
20120041464 Monetti et al. Feb 2012 A1
20120041474 Eckhouse et al. Feb 2012 A1
20120041475 Ferrera et al. Feb 2012 A1
20120046686 Wilson et al. Feb 2012 A1
20120065660 Ferrera et al. Mar 2012 A1
20120071964 Cattaneo et al. Mar 2012 A1
20120078140 Nita Mar 2012 A1
20120078285 Griffin Mar 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120116443 Ferrera et al. May 2012 A1
Foreign Referenced Citations (42)
Number Date Country
0321912 Jun 1989 EP
1000590 May 2000 EP
1437097 Jul 2004 EP
2257248 Oct 2011 EP
2301450 Nov 2011 EP
2417919 Feb 2012 EP
2006-094876 Apr 2006 JP
WO-9403127 Feb 1994 WO
WO9855173 Dec 1998 WO
WO0032265 Jun 2000 WO
WO0053120 Sep 2000 WO
WO-0108743 Feb 2001 WO
WO0136034 May 2001 WO
WO0145569 Jun 2001 WO
WO03011188 Feb 2003 WO
WO03017823 Mar 2003 WO
WO 2007089897 Aug 2007 WO
WO2007121005 Oct 2007 WO
WO 2008117256 Oct 2008 WO
WO 2008117257 Oct 2008 WO
WO-2008124728 Oct 2008 WO
WO2009105710 Aug 2009 WO
WO2009124288 Oct 2009 WO
WO2009126747 Oct 2009 WO
WO2010010545 Jan 2010 WO
WO2010023671 Mar 2010 WO
WO2010046897 Apr 2010 WO
WO2010049121 May 2010 WO
WO2010062363 Jun 2010 WO
WO2010102307 Sep 2010 WO
WO2010115642 Oct 2010 WO
WO-2010121037 Oct 2010 WO
WO-2010121049 Dec 2010 WO
WO-2011054531 Jul 2011 WO
WO-2011095352 Aug 2011 WO
WO-2011133486 Oct 2011 WO
WO-2011135556 Nov 2011 WO
WO-2011144336 Nov 2011 WO
WO-2011147567 Dec 2011 WO
WO-2012009675 Jan 2012 WO
WO-2012025245 Mar 2012 WO
WO-2012025247 Mar 2012 WO
Non-Patent Literature Citations (16)
Entry
US 5,485,450, 8/1998, Mische et al. (withdrawn).
T.W. Duerig, D.E. Tolomeo, M. Wholey, An Overview of Superelastic Stent Design.
Michael E. Kelly, MD, et al., Recanalization of an Acute Middle Cerebral Artery Occlusion Using a Self-Expanding, Reconstrainable, Intracranial Microstent as a Temporary Endovascular Bypass; Stroke, Jun. 2008, pp. 1770-1773, vol. 39, issue 6, United States.
Eric Sauvegeau, MD et al., Middle Cerebral Artery Stenting for Acute Ischemic Stroke After Unsuccessful Merci Retrieval; Neurosurgery (Special Technical Report), Apr. 2007, pp. 701-706, vol. 60, issue 4, United States.
David M. Pelz, et al., Advances in Interventional Neuroradiology 2007; Stroke, Jan. 2008, pp. 268-272, vol. 39, issue 1, United States.
Philippa C. Lavallee, et al., Stent-Assisted Endovascular Thrombolysis Versus Intravenous Thrombolysis in Internal Carotid Artery Dissection with Tandem Internal Carotid and Middle Cerebral Artery Occlusion; Stroke, Aug. 2007, pp. 2270-2274, vol. 38, issue 8, United States.
E.I. Levy et al., Self-Expanding Stents for Recanalization of Acute Cerebrovascular Occlusions; AJNR, May 2007, pp. 816-822, vol. 28, United States.
Micro Therapeutics, Inc., DBA EV3 Neurovascular, Inc., Solitaire FR Revascularization Device, Instructions for Use, 70494-001 Rev. Mar. 2009.
Micro Therapeutics, Inc., DBA EV3 Neurovascular, Inc., Fully depolyable. Completely retrievable. Solitaire AB, Neurovascular Remodeling Device.
Robertson, Kathy, Stroke device startup lands National Science Foundation grant, Sacramento Business Journal, Oct. 23, 2009, Sacramento, California, USA.
Henkes, H. et al., “A Microcatheter-Delivered Highly-Flexible and Fully-Retrievable Stent, Specifically Designed for Intracranial Use,” Interventional Neuroradiology, vol. 9, pp. 391-393 (Dec. 2003).
Doerfler, A. et al., “A Novel Flexible, Retrievable Endovascular Stent System for Small-Vessel Anatomy: Preliminary In Vivo Data,” Am. J. Neuroradiol. vol. 26, pp. 862-868 (Apr. 2005).
Liebig, T. et al., “A novel self-expanding fully retrievable intracranial stent (SOLO): experience in nine procedures of stent-assisted aneurysm coil occlusion,” Neuroradiology vol. 48, pp. 471-478 (Jul. 2006).
Yavuz, K. et al., “Immediate and midterm follow-up results of using an electrodetachable, fully retrievable SOLO stent system in the endovascular coil occlusion of wide-necked cerebral aneurysms,” J. Neurosurg. vol. 107, pp. 49-55 (Jul. 2007).
“Penumbra, Inc. Enrolls First Patients in PULSE Clinical Trial to Evaluate a Fully Retrievable, Dense Mesh Temporary Stent for Immediate Flow Restoration in Interventional Acute Ischemic Stroke Treatment,” Business Wire, Nov. 1, 2010, downloaded at http://www.businesswire.com/news/home/20101101006991/en/Penumbra-Enrolls-Patients-PULSE-Clinical-Trial-Evaluate.
Wakhloo, et al., “Retrievable Closed Cell Intracranial Stent for Foreign Body and Clot Removal,” Neurosurgery, May 2008.
Related Publications (1)
Number Date Country
20100100106 A1 Apr 2010 US
Provisional Applications (3)
Number Date Country
61044392 Apr 2008 US
61057613 May 2008 US
61166725 Apr 2009 US